These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1398 related items for PubMed ID: 16762610

  • 1. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
    Lind P, Kohlfürst S.
    Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
    [Abstract] [Full Text] [Related]

  • 2. Value of the negative PET-FDG in the middle term follow-up of differentiated thyroid cancer in patients with negative 131 I-Na scan and elevated thyroglobulin serum levels.
    Pachón-Garrudo VM, Cuenca-Cuenca JI, Ruiz-Franco-Baux J, Borrego-Dorado I, Tirado-Hospital JL, Navarro-González E, Vázquez-Albertino R.
    Rev Esp Med Nucl Imagen Mol; 2012 Jul; 31(6):315-21. PubMed ID: 23084014
    [Abstract] [Full Text] [Related]

  • 3. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
    Gallowitsch HJ, Mikosch P, Kresnik E, Unterweger O, Gomez I, Lind P.
    J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
    [Abstract] [Full Text] [Related]

  • 4. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels.
    Muros MA, Llamas-Elvira JM, Ramírez-Navarro A, Gómez MJ, Rodríguez-Fernández A, Muros T, López de la Torre M, Becerra A, Carreras JL.
    Am J Surg; 2000 Jun; 179(6):457-61. PubMed ID: 11004330
    [Abstract] [Full Text] [Related]

  • 5. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
    Sergieva S, Hadjieva T, Doldurova M, Stefanova S, Dudov A.
    J BUON; 2006 Jun; 11(4):511-8. PubMed ID: 17309186
    [Abstract] [Full Text] [Related]

  • 6. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P, Kuhn-Lansoy C, Edet-Sanson A, Hapdey S, Modzelewski R, Hitzel A, d'Anjou J, Basuyau JP.
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [Abstract] [Full Text] [Related]

  • 7. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans.
    Altenvoerde G, Lerch H, Kuwert T, Matheja P, Schäfers M, Schober O.
    Langenbecks Arch Surg; 1998 Apr; 383(2):160-3. PubMed ID: 9641890
    [Abstract] [Full Text] [Related]

  • 8. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL, Rodríguez Rodríguez JR, Borrego Dorado I, Navarro González E, Tirado Hospital JL, Vázquez Albertino R.
    Rev Esp Med Nucl; 2007 Apr; 26(3):138-45. PubMed ID: 17524307
    [Abstract] [Full Text] [Related]

  • 9. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
    Chung JK, So Y, Lee JS, Choi CW, Lim SM, Lee DS, Hong SW, Youn YK, Lee MC, Cho BY.
    J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
    [Abstract] [Full Text] [Related]

  • 10. [Use of 18F FDG-PET in patients with suspicion of recurrent differentiated thyroid cancer by elevated antithyroglobulin antibodies levels and negative ¹³¹I scan].
    Sanz Viedma S, Borrego Dorado I, Rodríguez Rodríguez JR, Navarro González E, Vázquez Albertino R, Fernández López R, Agudo Martínez A.
    Rev Esp Med Nucl; 2011 Jun; 30(2):77-82. PubMed ID: 21334773
    [Abstract] [Full Text] [Related]

  • 11. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
    Lind P, Gallowitsch HJ.
    Acta Med Austriaca; 1996 Jun; 23(1-2):69-75. PubMed ID: 8767519
    [Abstract] [Full Text] [Related]

  • 12. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma.
    Frilling A, Tecklenborg K, Görges R, Weber F, Clausen M, Broelsch EC.
    Ann Surg; 2001 Dec; 234(6):804-11. PubMed ID: 11729387
    [Abstract] [Full Text] [Related]

  • 13. Detecting metastatic neck lymph nodes in papillary thyroid carcinoma by 18F-2-deoxyglucose positron emission tomography and Tc-99m tetrofosmin single photon emission computed tomography.
    Wu YJ, Wu HS, Yen RF, Shen YY, Kao CH.
    Anticancer Res; 2003 Dec; 23(3C):2973-6. PubMed ID: 12926147
    [Abstract] [Full Text] [Related]

  • 14. Follow-up of differentiated thyroid cancer.
    Pacini F.
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S492-6. PubMed ID: 12192551
    [Abstract] [Full Text] [Related]

  • 15. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma.
    Shiga T, Tsukamoto E, Nakada K, Morita K, Kato T, Mabuchi M, Yoshinaga K, Katoh C, Kuge Y, Tamaki N.
    J Nucl Med; 2001 Mar; 42(3):414-9. PubMed ID: 11337516
    [Abstract] [Full Text] [Related]

  • 16. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level.
    Na SJ, Yoo IeR, O JH, Lin C, Lin Q, Kim SH, Chung SK.
    Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605
    [Abstract] [Full Text] [Related]

  • 17. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?
    Bannas P, Derlin T, Groth M, Apostolova I, Adam G, Mester J, Klutmann S.
    Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540
    [Abstract] [Full Text] [Related]

  • 18. Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence.
    Rosario PW, Furtado Mde S, Mineiro Filho AF, Lacerda RX, Calsolari MR.
    Thyroid; 2012 Nov; 22(11):1165-9. PubMed ID: 23050784
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 70.